<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03090152</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0721</org_study_id>
    <nct_id>NCT03090152</nct_id>
  </id_info>
  <brief_title>Minimal Opioid Use After Total Hip Replacement (THR)</brief_title>
  <official_title>Minimal Opioid Use After Total Hip Replacement (THR): a Blinded Randomized Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total hip arthroplasty can be associated with significant postoperative pain. Side effects of&#xD;
      pain management may impair participation in physical therapy and slow readiness for discharge&#xD;
      from the hospital. In a previous study done by the investigators' group, epidural patient&#xD;
      controlled analgesia (EPCA) with a hydromorphone containing solution appeared to have a more&#xD;
      favorable pain profile with ambulation, but greater side effects compared to injection of a&#xD;
      peri-articular cocktail. The use of opioid was greater in the peri-articular injection group&#xD;
      (PAI). There was no difference in length of stay. In view of the controversy over opioid use,&#xD;
      the investigators would like to develop an optimal opioid sparing pain management approach by&#xD;
      comparing 3 different protocols 1) Plain local anesthetic EPCA; 2) PAI; 3) EPCA + PAI; all in&#xD;
      conjunction with a multimodal opioid sparing pain regimen. The goal would be to maximize pain&#xD;
      control while minimizing opioid use and side-effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Long acting narcotics or scheduled doses of narcotics are often used as part of a multimodal&#xD;
      pain regimen. In this study, this is eliminated. Instead, it uses a cocktail of different&#xD;
      drugs including intraoperative Ketamine use (NMDA receptor antagonist), intra-op Benadryl (to&#xD;
      decrease excitation of nociceptors) and IV Tylenol. The narcotic free regimen starts&#xD;
      preoperatively with the use of Aspirin,Clonidine patch, Cymbalta (Duloxetine), and is&#xD;
      maintained both intraoperatively and post operatively. Baby ASA (81mg) is being used as an&#xD;
      anti-inflammatory agent. A number of studies including the one by Morris et al. (2009), have&#xD;
      shown via in vitro experiments that low dose aspirin decreases polymorphonuclear leukocyte&#xD;
      and macrophage accumulation. It inhibits thromboxane making it an antithrombotic agent as&#xD;
      well. The concern with aspirin has been major bleeding. Several studies in the orthopedic&#xD;
      patient population using â‰¤81 mg of aspirin have shown that it does not increase bleeding&#xD;
      (Cuellar, Mantz). At HSS, patients are routinely continued on baby aspirin when needed for&#xD;
      its cardio protective effect. Devereaux in the POISE trial did show an increased risk of&#xD;
      bleeding when ASA was given preoperatively at a dose of 200 mg. In our study, all patients&#xD;
      will be given intravenous tranexamic acid which should mitigate against the risk of bleeding.&#xD;
      Duloxetine is also being added. In a recent study done at HSS. Duloxetine was found to&#xD;
      decrease the amount of opioid use and nausea. If found to be more effective with the use of&#xD;
      EPCA vs. PAI or combination of the two, a new way of managing postop pain while minimizing&#xD;
      Nnartcuoreti co fu Ssetu adsy per CDC recommendation will be helpful in managing patients&#xD;
      post-operatively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2017</start_date>
  <completion_date type="Actual">September 27, 2019</completion_date>
  <primary_completion_date type="Actual">June 28, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid use</measure>
    <time_frame>within 24 hours after surgery</time_frame>
    <description>Oral morphine equivalents, cumulative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain at rest</measure>
    <time_frame>Postoperative Day 1,2,3,7,90</time_frame>
    <description>via NRS (Numeric Pain Rating Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain with activity</measure>
    <time_frame>Postoperative Day 1,2,3,7,90</time_frame>
    <description>via NRS (Numeric Pain Rating Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid side effects</measure>
    <time_frame>Postoperative Day 1,2</time_frame>
    <description>via ORSDS (Opioid-Related Symptom Distress Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>Postoperative Day 1,2,3,7</time_frame>
    <description>via Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative pain</measure>
    <time_frame>Postoperative Day 1</time_frame>
    <description>via PAINOUT (Improvement in postoperative PAIN OUTcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic pain assessed with S-LANSS</measure>
    <time_frame>Postoperative Day 7, Postoperative Day 90</time_frame>
    <description>via S-LANSS (Self-report Leeds Assessment of Neuropathic Symptoms and Signs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic pain assessed with SF-8</measure>
    <time_frame>Postoperative Day 7, Postoperative Day 90</time_frame>
    <description>via SF-8 (Short Form Health Survey)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of recovery</measure>
    <time_frame>Postoperative Day 1,2,3</time_frame>
    <description>Via QoR-40 (Quality of Recovery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readiness for discharge time</measure>
    <time_frame>From end of surgery until the date/time of first documented clearance for discharge, assessed up to 1 week.</time_frame>
    <description>When patient meets all readiness for discharge criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blinding Assessment</measure>
    <time_frame>Assessed on day of discharge, up to 24 hours.</time_frame>
    <description>What group do you think you were in</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption in first 3 days post-op</measure>
    <time_frame>Postoperative day 0,1,2,3</time_frame>
    <description>Opioids consumed in the first 3 after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No opioids consumed</measure>
    <time_frame>0 to 24 hours post-operatively</time_frame>
    <description>Number of patients who did not consume any opioids</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Osteoarthritis, Hip</condition>
  <arm_group>
    <arm_group_label>Periarticular Injection (PAI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin and nerve pain medications including duloxetine and clonidine patch prior to surgery.&#xD;
Peri-articular injection in the operating room&#xD;
Combined Spinal Epidural with 1.5% Mepivacaine 4cc&#xD;
A pain regimen while in the hospital that includes EPCA (saline) Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV&#xD;
Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epidural Patient-Controlled Analg (EPCA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin and nerve pain medications including duloxetine and clonidine patch prior to surgery.&#xD;
Combined Spinal Epidural with 1.5% Mepivacaine 4cc&#xD;
A pain regimen while in the hospital that consists of Epidural PCA (EPCA) with 0.06% bupivacaine. Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV The EPCA will be removed when pain is well-controlled. Other medications, including opioids, will be available.&#xD;
Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAI + EPCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin and nerve pain medications including duloxetine and clonidine&#xD;
Combined Spinal Epidural with 1.5% Mepivacaine 4cc&#xD;
Anesthetic, Antiemetic and peri-articular injection in the operating room&#xD;
A pain regimen while in the hospital that consists of EPCA (with 0.06% bupivacaine) Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV The EPCA will be removed when pain is well-controlled. Other medications, including opioids, will be available.&#xD;
Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Periarticular injection (Deep injection)</intervention_name>
    <description>Deep injection of &quot;cocktail&quot; containing Bupivacaine with Epi, 30mL; Morphine, 8mg/mL, 1mL; Methyprednislone, 40mg/mL, 1mL; Cefazolin, 500mg in 10 mL; saline, 22mL into the anterior capsule, the periosteum, the gluteus maximus, and the abductor muscles and fascia lata.</description>
    <arm_group_label>PAI + EPCA</arm_group_label>
    <arm_group_label>Periarticular Injection (PAI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Periarticular injection (Superficial injection)</intervention_name>
    <description>Superficial injection of 40mL 0.25% Bupivacaine into subcutaneous tissue prior to wound closure.</description>
    <arm_group_label>PAI + EPCA</arm_group_label>
    <arm_group_label>Periarticular Injection (PAI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>EPCA: Bupivacaine 0.06%.</description>
    <arm_group_label>Epidural Patient-Controlled Analg (EPCA)</arm_group_label>
    <arm_group_label>PAI + EPCA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>EPCA: Saline.</description>
    <arm_group_label>Periarticular Injection (PAI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient with osteoarthritis scheduled for primary total hip arthroplasty with a&#xD;
             participating surgeon&#xD;
&#xD;
          -  Planned use of regional anesthesia&#xD;
&#xD;
          -  Planned posterolateral surgical approach&#xD;
&#xD;
          -  Age Range 45-80&#xD;
&#xD;
          -  Ability to follow study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any patient with age &lt;45 or &gt;80&#xD;
&#xD;
          -  Any patient with planned anterior surgical approach&#xD;
&#xD;
          -  Any patient with prior major ipsilateral hip surgery&#xD;
&#xD;
          -  Any patient intending to receive general anesthesia&#xD;
&#xD;
          -  Any patient with an ASA of IV&#xD;
&#xD;
          -  Any patient with insulin-dependent diabetes&#xD;
&#xD;
          -  Any patient with hepatic (liver) failure (history of cirrhosis or elevated LFT's)&#xD;
&#xD;
          -  Any patient with chronic renal (kidney) failure (formal diagnosis of renal disease of&#xD;
             elevated creatinine)&#xD;
&#xD;
          -  Any patient with history of gastric (stomach) ulcer&#xD;
&#xD;
          -  Chronic opioid use (taking opioids for &gt;3 mo duration on a daily basis)&#xD;
&#xD;
          -  Chronic analgesic use (i.e. lyrica, gabapentin) for &gt;3 mo duration&#xD;
&#xD;
          -  Stress dose steroids&#xD;
&#xD;
          -  Use of antidepressants&#xD;
&#xD;
          -  Contraindications to aspirin&#xD;
&#xD;
          -  Allergy to any of the medications (or adhesives) involved in the study protocol&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Non-English speakers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kethy Jules-Elysee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Total Hip Replacement</keyword>
  <keyword>Total Hip Arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 25, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT03090152/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

